EUVIMEDEUVIMED entdecken
Multizentrische Studie

GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation

Haisheng Wu, Yiling Yan, Manrong Xu, Ruixin Wang iD, Gang Hu iD, Yun Shen iD, Shengdi Lu

Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6358-6369

DOI: 10.1111/dom.70847 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 07.05.2026. Verfasst von Haisheng Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Bariatric Surgery, Obesity, Morbid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Suboptimal weight loss affects 20%–35% of patients after metabolic bariatric surgery (MBS). Randomised evidence on glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) pharmacotherapy in this population is limited to small, single‐center Western trials. No data exist from Chinese populations.

Objective

To emulate a target trial comparing GLP‐1 RA initiation with standard care among suboptimal responders to MBS in a Chinese multicenter cohort. Design, Setting, and Participants Target trial emulation using electronic health record (EHR) data from two Tertiary A teaching hospitals in China (March 2019 to June 2024). Eligible adults aged 18–65 years had undergone sleeve gastrectomy (SG) or Roux‐en‐Y gastric bypass (RYGB), were 12–36 months post‐surgery with body mass index (BMI) ≥ 28 kg/m 2 and suboptimal weight loss. The clone‐censor‐weight approach handled the 30‐day grace period. 1:5 propensity score matching yielded 624 patients (104 GLP‐1 RA, 520 standard care).

Interventions

Strategy A: GLP‐1 RA initiated within 30 days. Strategy B: standard post‐MBS care without GLP‐1 RA. Main Outcome Percentage of total body weight loss (%TBWL) at 12 months.

Results

Mean age was 36.4 years; 66% were female; mean BMI was 33.7 kg/m 2 . At 12 months, mean %TBWL was 7.5% in the GLP‐1 RA group versus 1.2% in the standard care group (difference, 6.28 percentage points; 95% CI, 5.50 to 7.07; p < 0.001). The ≥ 5% TBWL responder rate was 75% versus 7%. The per‐protocol effect was 6.44 percentage points (95% CI, 5.65 to 7.23). Results were consistent across surgery types, BMI thresholds, diabetes status, and all sensitivity analyses. Conclusions and Relevance In this target trial emulation, GLP‐1 RA initiation was associated with clinically meaningful weight loss among Chinese suboptimal responders to MBS. These findings extend Western randomised trial evidence to a Chinese multicenter real‐world setting and support the integration of GLP‐1 RA pharmacotherapy into post‐bariatric care pathways in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossGlucagon-Like Peptide-1 Receptor AgonistsBariatric SurgeryObesity, MorbidHumansFemaleAdultMiddle AgedMaleChinaGastric BypassTreatment OutcomeGlucagon-Like Peptide-1 ReceptorBody Mass Index

Stichwörter der Autor:innen

GLP‐1bariatric surgerycohort studyweight control

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Department of General Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Endocrinology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • School of Public Health, Fudan University, Shanghai, China.
  • Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.

ORCID-Profile: Ruixin Wang, Gang Hu, Yun Shen

Zitieren

APA

Wu, H., Yan, Y., Xu, M., Wang, R., Hu, G., Shen, Y., & Lu, S. (2026). GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation. Diabetes, Obesity and Metabolism, 28(7), 6358-6369. https://doi.org/10.1111/dom.70847

Vancouver

Wu H, Yan Y, Xu M, Wang R, Hu G, Shen Y, et al. GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation. Diabetes, Obesity and Metabolism. 2026;28(7):6358-6369. doi:10.1111/dom.70847

BibTeX
@article{Wu2026,
  author = {Wu, Haisheng and Yan, Yiling and Xu, Manrong and Wang, Ruixin and Hu, Gang and Shen, Yun and Lu, Shengdi},
  title = {GLP ‐1 Receptor Agonists and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Target Trial Emulation},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {7},
  pages = {6358--6369},
  doi = {10.1111/dom.70847}
}
Kostenlos starten →